<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308088">
  <stage>Registered</stage>
  <submitdate>19/08/2009</submitdate>
  <approvaldate>26/08/2009</approvaldate>
  <actrnumber>ACTRN12609000740291</actrnumber>
  <trial_identification>
    <studytitle>Comparison of two different flow rates of local anaesthetic for pain relief after shoulder rotator cuff repair</studytitle>
    <scientifictitle>A comparison of Ropivacaine 2mL/hr and 5mL/hr for ambulatory patient controlled interscalene analgesia after rotator cuff repair</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Patient initiated mandatory intermittent boluses for ambulatory continuous interscalene analgesia: an effective strategy for optimising analgesia versus side effects</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain relief after shoulder rotator cuff repair</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.2% Ropivacaine at flow rate of 2mL/hr with regular 6 hourly 5 ml boluses for continuous interscalene block after rotator cuff repair for 48 hours postoperatively as required by the patient.</interventions>
    <comparator>0.2% Ropivacaine at flow rate of 5mL/hr with as required only 5 ml boluses for continuous interscalene block after rotator cuff repair for  48 hours postoperatively as required by the patient.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain after rotator cuff repair, assessed by patient interrogation regarding analgesic consumption and pain scores using numerical rating pain score (NRPS).</outcome>
      <timepoint>Day 1 and 2 post operatively.  Analgesic requirements and pain scores (0-10) measured in the afternoon of Day 1 and Day 2 following surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Arm numbness/weakness</outcome>
      <timepoint>First 48 post operative hours.
1-2 days post operatively.  Arm numbness and arm weakness (numerical rating scale) measured in the afternoon of Day 1 and Day 2 following surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients requiring continuous interscalene analgesia following rotator cuff repair under the care of the two investigators.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Patient refusal/inability to consent.
2. Allergy amide local anaesthetic (LA).
3. Existing neurological disorders/neuropathy of the operative extremity.
4. Infection at site of needle puncture.
5. Severe respiratory disease.
6. Chronic opioid therapy.
7. Intolerance of all non-steroidal anti-inflammatory drugs (NSAIDs)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A dedicated research assistant will invite patients to be included in the study and will perform the post operative phone call on days 1 and 2.  The  investigators will place all interscalene catheters.  The patients Post Anaesthesia Care Unit (PACU) nurse will be asked to record the patients pain score on arrival in the PACU.  Patients will be asked simple questions on post operative day 1 through 2.  
Assignment of patient to 2mL/hr or 5mL/hr flow rate of local anaesthetic will be delivered in a sealed opaque envelope.</concealment>
    <sequence>A computerised random number generator will be used to assign the patient to one of the 2 groups.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>13/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Fredrickson</primarysponsorname>
    <primarysponsoraddress>Anaesthesia Institute P O Box 109 199 Newmarket Auckland 1149</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>I-Flow Corporation</fundingname>
      <fundingaddress>20202 Windrow Drive Lake Forest CA 92630</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to further refine the optimal infusion of ropivacaine to be used for continuous interscalene analgesia after shoulder surgery. A prevuous study compared ropivacaine 0.2% and 0.4% given at the same rate following rotator cuff repair. Analysis of the data has revealed little difference between the groups in any of the outcome parameters.

We propose to continue the study with similar methodology, but this time use ropivacaine 0.2% at two different flow rates, 2 ml/h and 5 ml/hr. We will be assessing effectiveness of the analgesia and side effects over the first 2 days postoperatively. essentially, the main hypothesis is that the higher flow rate will improve the pain relief after surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Private Bag 92 522
Wellesley Street
Auckland 1141</ethicaddress>
      <ethicapprovaldate>6/05/2009</ethicapprovaldate>
      <hrec>NTX/08/04/026</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket 
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Watkin</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>